EGFR and neoplasm: CAFs, one of the most abundant components within TME, promote tumor malignancy and confer anti-EGFR therapy resistance through multiple mechanisms, including ECM remodeling, secretion of soluble molecules, exosome vesicle delivery, and metabolic crosstalk [52].